Publications by authors named "Matias Fusini"
Metronomic chemotherapy (MCT) is a cancer therapeutic approach characterized by low dose drug chronic administration and limited or null toxicity. Obesity-induced metabolic alterations worsen cancer prognosis and influence the intestinal biochemical barrier, altering the Multidrug resistance-associated protein 2 (Mrp2) and Multidrug resistance protein-1 (Mdr-1), efflux pumps that transport chemotherapeutic drugs. Obesity and cancer are frequent co-morbidities; thus, our aim was to evaluate the effectiveness and toxicity of MCT with cyclophosphamide (Cy) in obese mice with metabolic alterations bearing a mammary adenocarcinoma.
View Article and Find Full Text PDFArticle Synopsis
- This study looked at how a protein called COX-2 affects liver damage caused by a condition called cholestasis, where bile can't flow properly.
- Scientists used specially modified mice that always express COX-2 in their liver cells to see if it helps protect against liver injury.
- The results showed that these COX-2 mice had less liver damage and inflammation, improved bile acid processing, and were better at handling stress in the liver compared to regular mice.
Metronomic chemotherapy refers to the minimum biologically effective doses of a chemotherapy agent given as a continuous regimen without extended rest periods. Drug repurposing is defined as the use of an already known drug for a new medical indication, different from the original one. In oncology the combination of these two therapeutic approaches is called "Metronomics".
View Article and Find Full Text PDF